GLP-1 side effects: rates, timing and warning signs
Nausea, diarrhea, vomiting and constipation appear in both Wegovy and Zepbound trial results. But a trial average cannot predict your symptoms or give you a personal recovery date. This guide separates product-specific rates from decisions to discuss with your prescriber.
This is an AI-assisted source review, not a personal treatment account or an independent clinical review. We checked the linked prescribing information; we did not examine patients or test a treatment protocol.
Warning signs come before the timeline
For Wegovy, the medication guide says to stop treatment and seek immediate medical help for serious allergic symptoms, including breathing difficulty or face/throat swelling. Stop treatment and call your clinician immediately for severe abdominal pain that persists, with or without vomiting. Persistent nausea, vomiting or diarrhea also needs prompt contact because dehydration can injure the kidneys. Wegovy medication guide
These examples are not a complete safety checklist. Read the medication guide supplied with your own product. Do not use this article’s calendar or percentages to dismiss a new or severe symptom.
Trial rates: keep the products separate
The following are percentages of adults reporting each reaction, not monthly risks. They come from separate trial populations and are not a head-to-head tolerability ranking.
Wegovy 2.4 mg weekly injection
| Reaction | Wegovy | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
The table covers adults with obesity or overweight in the label’s weight-reduction studies (2,116 treated; 1,261 placebo). It does not describe Ozempic, oral Wegovy, other doses or compounded products. Wegovy label, section 6.1, table 3
Zepbound weekly injection
| Reaction | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 25% | 29% | 28% | 8% |
| Diarrhea | 19% | 21% | 23% | 8% |
| Vomiting | 8% | 11% | 13% | 2% |
| Constipation | 17% | 14% | 11% | 5% |
These are pooled adult weight-reduction studies 1 and 2, not Mounjaro diabetes-trial rates. Discontinuation for gastrointestinal reactions was 1.9%, 3.3% and 4.3% across these doses, versus 0.5% with placebo. Zepbound label, section 6.1
Timing: dose changes matter, but symptoms have no fixed deadline
Zepbound’s pooled studies recorded most nausea, vomiting and diarrhea events during dose escalation, with fewer events over time. That finding does not establish that everyone recovers by month four or six. Zepbound label
For Wegovy injection, the label allows the prescriber to consider delaying escalation four weeks when a dose is not tolerated. Ask your clinician before changing the schedule; this is not permission to adjust it yourself. Wegovy dosing instructions, section 2.2
We removed the previous month-by-month personal stories because we could not substantiate them. We also removed blanket advice about evening injections, probiotics, magnesium and fixed protein/fluid targets. They were not supported as a universal side-effect treatment plan.
Prepare a useful message for your prescriber
Use this editorial checklist to describe what is happening, not to diagnose yourself:
- Product name, formulation, prescribed dose and date of the last dose change.
- Symptoms, when they started and whether they are worsening.
- Whether you can eat and keep fluids down.
- Other medicines or supplements, including anything started for the symptoms.
- Your question: should the treatment schedule or symptom-management plan change?
A specific message is more useful than “month two feels bad.” For example: “I increased my prescribed dose on [date]. Since then I have had [symptom] [frequency]. I can/cannot keep fluids down.” Seek urgent care when appropriate rather than waiting for an online reply.
What to review before the next dose
Zepbound’s label also covers thyroid-tumor contraindications, pregnancy, low blood sugar, anesthesia and oral contraceptives. Oral hormonal contraception needs an alternative or added barrier method for four weeks after starting and after each dose increase. Review your medication guide and personal risks with your clinician. Zepbound prescribing information
A lower trial discontinuation percentage is not enough to choose a medication. This page does not recommend switching drugs or rank providers for treating adverse effects.